Charles River (CRL) Q4 2025 earnings review
Bookings Rebound Shadows Massive Write-Downs
Charles River reported a messy Q4. While management touted a 'substantial improvement' in DSA net bookings and stabilization in biopharma demand, the financials paint a harsh picture. The company booked a massive $376M impairment charge (Goodwill + Intangibles) related to its Biologics and Cell Solutions businesses, pushing GAAP EPS to a loss of $(5.62). Non-GAAP EPS fell 10% YoY to $2.39, hampered by a 180bps margin compression. 2026 guidance offers a glimmer of hope with 4-9% EPS growth, but organic revenue is expected to remain flat to negative.
🐂 Bull Case
The core Discovery and Safety Assessment (DSA) segment saw 'substantial improvement' in net bookings in Q4. This is the critical leading indicator investors have been waiting for, suggesting the demand trough has passed.
Despite flat revenue guidance for 2026 (-1% to Flat organic), Non-GAAP EPS is guided to grow 4-9%. This demonstrates that restructuring initiatives and efficiency gains are successfully protecting the bottom line.
🐻 Bear Case
The company recorded $376 million in impairments (intangibles and goodwill) for Biologics Solutions and Cell Solutions. This is a continued admission that previous acquisitions and valuations in the CDMO/Manufacturing space were significantly overpriced.
Non-GAAP operating margin compressed to 18.1% in Q4 from 19.9% a year ago. The core DSA segment margin collapsed to 20.1% (from 24.7%), driven by higher study costs and staffing, indicating negative operating leverage.
⚖️ Verdict: ⚪
Neutral. The bookings improvement is the green shoot the market needed, but the massive GAAP write-downs and sharp margin compression in the core DSA business indicate significant execution challenges remain. 2026 looks like a transition year.
Key Themes
Biologics & Cell Solutions Impairment
Management recorded a massive non-cash impairment totaling $376 million ($211M intangible asset impairment + $165M goodwill impairment) related to the Biologics Solutions and Cell Solutions reporting units. This follows a $215M impairment in the prior year, signaling persistent underperformance and value destruction in the Manufacturing/CDMO strategy.
DSA Margin Deterioration
The Discovery and Safety Assessment (DSA) segment, typically the profit engine, saw Non-GAAP operating margins contract sharply to 20.1% in Q4 from 24.7% a year ago and 25.4% in Q3. Management cited 'higher study-related direct costs' and staffing. This level of compression on a 3.3% organic revenue decline suggests a rigid cost structure.
Bookings Stabilization
CEO James Foster cited 'substantial improvement in DSA net bookings' in Q4. While revenue lags (DSA revenue was still down 3.3% organic), bookings are the forward-looking metric that matters most. This validates the narrative that the biopharma demand environment has stabilized.
Manufacturing Segment Weakness
Manufacturing Solutions revenue fell 2.1% organically. While Microbial Solutions grew, the CDMO business continues to be a drag, driven by the loss of a large commercial client in 2025. This segment is the source of the massive impairments recorded this quarter.
Microbial Solutions Resilience
Within the struggling Manufacturing segment, Microbial Solutions remains a bright spot, offsetting some of the CDMO weakness. The outlook for 2026 explicitly cites 'continuation of solid demand trends' in this high-margin niche.
Other KPIs
Solid generation. Calculated as Operating Cash Flow ($737.6M) minus CapEx ($219.1M). This provides ample coverage for the company's debt obligations and allows for strategic flexibility despite the GAAP earnings volatility.
Stable/Slight Decline. Revenue was $206.3M. The decline was driven by lower large research models (NHPs) and small models in North America, partially offset by growth in China and Europe. This segment remains a low-growth cash cow.
Non-GAAP Net Income fell 13.0% while Pre-tax Income fell less severely. Management explicitly cited a 'higher tax rate' as a primary driver for the EPS decline, alongside lower operating margins.
Guidance
Stable. The company expects a return to growth in H2 2026, driven by the current bookings improvement. However, the full year remains muted, reflecting the lag time between bookings and revenue recognition.
Accelerating. Implies 4% to 9% growth over 2025's $10.28. This growth exceeds revenue growth, driven by cost savings from restructuring and the accretive impact of the K.F. (Cambodia) acquisition.
Improving. Includes a net 0.0% to -0.5% impact from divestitures and a -1.0% to -1.5% FX headwind. The return to positive reported growth is a psychological positive after two years of declines.
Key Questions
DSA Margin Recovery
DSA margins dropped 530 basis points sequentially to 20.1%. Is this the new normal due to staffing backfills, or a temporary mismatch before revenue ramps? What is the margin assumption embedded in the 2026 EPS guidance?
Impairment contagion
With $376M in write-downs this quarter primarily in Biologics/CDMO, does management believe the carrying value of the remaining CDMO assets is now appropriate, or is there further risk if utilization doesn't improve?
Bookings to Revenue Conversion
Management cites robust Q4 bookings but guides for H1 2026 organic revenue to likely remain negative (given the back-half growth comment). Has the conversion cycle lengthened, or is the backlog mix shifting to longer-duration studies?